Nefazodone
نفازودون
🧠 Nervous SystemPhenylpiperazine antidepressant
Market / country: 🇺🇸 USA
Nefazodone (US)
🧮 Dose calculator
Major depressive disorder · Regimen source: FDA Nefazodone · Dosage and Administration
- • Increase by 100–200 mg/day at intervals of at least 1 week. Elderly or debilitated: start 50 mg twice daily. Weigh hepatic failure risk when choosing. FDA Nefazodone · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Concomitant terfenadine, astemizole, cisapride, pimozide or carbamazepine; prior withdrawal from nefazodone for liver injury; hypersensitivity to nefazodone or phenylpiperazine antidepressants. Avoid triazolam in most patients. FDA Nefazodone · Contraindications
Warnings
- • Boxed warning: life-threatening hepatic failure (about 1 death or transplant per 250,000–300,000 patient-years); suicidality in children and young adults. FDA Nefazodone · Boxed Warning
Formulations
- 100 mg tablet (scored) — tablet 🇺🇸 USA FDA Nefazodone · How Supplied
- 50 mg tablet — tablet 🇺🇸 USA FDA Nefazodone · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Nefazodone · Pregnancy
“Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Nefazodone · Nursing Mothers
“Because many drugs are excreted in human milk, caution should be exercised when nefazodone is administered to a nursing woman.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Nefazodone · Boxed Warning
“Nefazodone hydrochloride tablets are not approved for use in pediatric patients (see WARNINGS, Clinical Worsening and Suicide Risk ;”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Nefazodone · Geriatric Use
“The usual precautions should be observed in elderly patients who have concomitant medical illnesses or who are receiving concomitant drugs.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA076037
- DailyMed (FDA label)FDA Nefazodone
- MedlinePlus (NIH)Nefazodone
- WHO ATC/DDDN06AX06
- Darooyab (Iran)Nefazodone
🇮🇷 Not found in Iran list Darooyab · G-599/Nefazodone
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Nefazodone · How SuppliedFDA Nefazodone · Dosage and AdministrationFDA Nefazodone · ContraindicationsFDA Nefazodone · Boxed WarningFDA Nefazodone · PregnancyFDA Nefazodone · Nursing MothersFDA Nefazodone · Geriatric UseFDA Nefazodone · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-599/Nefazodone
- Clinical review⚠ Unverified